A Mirna-Based Signature Predicts Development of Disease Recurrence in HER2 Positive Early Breast Cancer after Adjuvant Trastuzumab-Based Treatment.
Du Feng,Peng Yuan,Jiayu Wang,Fei Ma,Yang Luo,Binghe Xu
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.e12070
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:e12070 Background: Adjuvant trastuzumab is the standard treatment for early HER2 positive breast cancer. However, 15%-22% of patients still suffered disease recurrence after adjuvant anti-HER2 treatment. A molecular prognostic model that can reliably stratify patients by risk of developing disease recurrence is urgently needed. Methods: All the patients included were diagnosed as HER2-postive breast cancer and received radical surgery followed by adjuvant trastuzuamb treatment. Using miRNA microarrays, we analyzed the FFPE tumor tissue from14 patients (7 recurrence vs.7 non-recurrence) and identified nine miRNAs that were differentially expressed. Then, we validated the expression of these miRNAs using qRT-PCR in training set (n = 101), and built the miRNA-based classifier using the Cox regression model. We further confirmed the prognostic accuracy of this signature in an internal testing set (n = 57), and an external independent testing set (n = 53) Results: We identified a two-microRNA signature that classify patients into those at high risk of disease progression (high-risk group), and those at low risk (low-risk group).DFS was significantly different between the two groups in each set of patients. In the training set, 5-year DFS was 89.2% for the low-risk group, and 59.0% for the high-risk group (hazard ratio [HR] 5.35, 95% CI 2.13-13.44; p < 0.001).In the internal testing set, 5-year DFS was 87.5% for the low-risk group, and 45.8% for the high-risk group (HR 3·71, 95% CI 1.08–12.74; p = 0.025), and in the external independent testing set, that was 80.1% for the low-risk group and 38.9% for the high-risk group (HR 3·43, 95% CI 1.35–8.69; p = 0.006). In the combined analysis of all patients (n = 211), the two-miRNA signature was an independent prognostic factor for prognosis, and had better predictive value than other clinicopathological factors. In combination with TNM stage, the model demonstrated the highest prognostic accuracy (AUC = 0.711, 95%CI 0.634-0.787). Conclusions: Our two-miRNA signature is a reliable prognostic and predictive tool for disease recurrence in patients with HER2 positive breast cancer who received adjuvant trastuzumab-based treatment.